SCHEDULE 13G: J.H. Whitney Group Discloses 7.3% Stake in Caris Life Sciences
Beneficial Ownership Disclosure
A group led by J.H. Whitney VI L.P. has reported beneficial ownership of 7.3% of Caris Life Sciences, Inc.'s common stock.
Summary
- J.H. Whitney VI L.P., J.H. Whitney Equity Partners VI, LLC, Paul R. Vigano, and Robert M. Williams, Jr. (collectively, the "Reporting Persons") have filed a Schedule 13G.
- The group beneficially owns 20,256,615 shares of Caris Life Sciences, Inc. common stock.
- This ownership represents 7.3% of the company's outstanding common stock.
- All shares are held with shared voting and shared dispositive power among the reporting persons.
- The event requiring this filing occurred on June 30, 2025.
Sentiment
Score: 5
Explanation: The filing is a standard disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's performance or prospects. It simply reports a factual ownership stake.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: Disclosure of a significant institutional stake may influence market perception and trading activity.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event requiring the filing of this statement. |
| 08/14/2025 | Date of the Joint Filing Agreement and signatures on the Schedule 13G. |
Keywords
Caris Life Sciences, J.H. Whitney, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Equity Stake, Biotechnology, Healthcare
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.